Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03029325 · ClinicalTrials.gov registry record

Molecular and Genetic Analysis of Lung Cancer

A clinical trial of Lung Cancer, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
15,000
Enrollment target
1
Study location

NCT03029325: Recruiting study of Lung Cancer, sponsored by Massachusetts General Hospital.

NCT03029325 is a study of Lung Cancer that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 15,000 participants, above the 899-participant average among 409 other Lung Cancer trials with a reported enrollment target (1569% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT03029325, a study of Lung Cancer, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
15,000 participants
Enrollment target
1
Study location

Study Summary

Investigators use a genome-wide approach within a case-control design to identify SNPs that show evidence of association with lung cancer risk and survival.

Primary Outcome

Study lung cancer development in a case control study. We will look at three separate outcome measures specified below

Conditions Studied

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 15,000 participants
Start Date 1993-06
Est. Completion 2026-09
Massachusetts General Hospital

2,032 total trials

What NCT03029325 shows while recruiting

NCT03029325 is an observational study that tracks outcomes without assigning an intervention. Its 15,000 participants enrollment target places it among the larger protocols in the corpus, above the 899-participant average among 409 other Lung Cancer trials with a reported enrollment target (1569% higher).

The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT03029325 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03029325 about?

NCT03029325 is a clinical study titled "Molecular and Genetic Analysis of Lung Cancer". Investigators use a genome-wide approach within a case-control design to identify SNPs that show evidence of association with lung cancer risk and survival.

What is the current status of trial NCT03029325?

This trial is currently recruiting. The enrollment target is 15,000 participants. The study started on 1993-06. Estimated completion is 2026-09.

What conditions does trial NCT03029325 study?

This clinical trial studies the following conditions: Lung Cancer.

Who is sponsoring clinical trial NCT03029325?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03029325 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03029325's enrollment target sits among peer trials

15,000 6th of 409 higher than 404 of 409 other Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00857922 · 15,000 participants

    Neurosciences Research Repository

  • NCT01137643 · 15,000 participants

    Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

  • NCT01550575 · 15,000 participants

    Patient Retrospective Outcomes (PRO)

  • NCT02253251 · 15,000 participants

    Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT03029325, the US trial registry maintained by the National Library of Medicine. NCT03029325 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.